AR and prostate cancer: While androgen deprivation therapy is initially effective, prostate cancer cells eventually acquire resistance against this therapy via several mechanisms, such as amplification, transcriptional upregulation, gene mutations, and/or the generation of splice variants (such as AR-V7) of AR [29].